Scinai Immunotherapeutics Ltd.
corporate_fare Company Profile
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for SCNI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for SCNI spans 6-K, F-1, 424B3, F-3.
Recent high-impact activity:
- Scinai CEO Letter: $8.1M Committed Orders and Runway to Late 2027 After $5.3M Net Raise
- Scinai Raises $4M in Private Placement and Warrant Inducement
- Scinai Lands $5.1M CDMO Deal, Expanding Clinical Manufacturing Footprint
- Scinai Registers 2.7M ADSs for Resale — Potential 67% Dilution Overhang
- Scinai Ends PC111 Partnership, Pivots to NanoAb Platform and CDMO Growth
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 179,643 shares in SCNI as of the October 15, 2026 settlement, a 802.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 27, 2026, 12.7% of SCNI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SCNI, detected from its recent SEC filings · based on capital-structure filings through 2026-09-24.
Resale Registration Finalized · Significant Potential Dilution
⚠ Dilution data last refreshed 2026-10-27; newer filings may not be reflected yet — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
SCNI files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.